Business
Availability of Poxel’s 2025 Half-Year Financial Report
LYON, France, December 18, 2025--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announced the availability of its half-year financial report as of June 30, 2025.
About this update from Poxel Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":256,"url":"https://media.zenfs.com/en/business-wire.com/7438c96d736cded1d7aea06ce517e4be"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cTGQqkhejYvSkLiQ8czOfg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUxMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7438c96d736cded1d7aea06ce517e4be","width":480,"height":256}},"lazy":false},{"type":"text","content":"LYON, France, December 18, 2025--(BUSINESS WIRE)--Regulatory News:","length":66,"tagName":"p"},{"type":"text","content":"POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announced the availability of its half-year financial report as of June 30, 2025.","length":363,"tagName":"p"},{"type":"text","content":"The half-year financial report includes:","length":40,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"the condensed consolidated financial statements for the first half of 2025, as of June 30, 2025;","length":96,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"the half-year activity report;","length":30,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"the certification of the person responsible for the half-year financial report;","length":79,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"the Statutory Auditors’ limited review report on the half-year financial information, which includes an inability to reach a conclusion due to the uncertainties surrounding going concern.","length":187,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":392,"olType":false},{"type":"text","content":"This document is available in French on Poxel’s website www.poxelpharma.com in the Investors / Shareholder Information / Regulatory Documentation section.","length":154,"tagName":"p"},{"type":"text","content":"About Poxel SA","length":14,"tagName":"p"},{"type":"text","content":"Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including ...